I am pleased to be engaged with healthcare policy making at the institutional, local, and national levels. Among other things:
I am a member of MEDCAC, the Medicare Evidence Development & Coverage Advisory Committee (2013-2015). MEDCAC reviews and evaluates medical literature, technology assessments, and examines data and information on the effectiveness and appropriateness of medical items and services that are covered under Medicare, or that may be eligible for coverage under Medicare. MEDCAC judges the strength of the available evidence and makes recommendations to CMS based on that evidence.
I co-chair the Minnesota POLST Task Force, a project housed by the Minnesota Medical Association
I testified, by invitation, before the U.S. President's Council on Bioethics.
I testified, by invitation, before the Minnesota Senate.
I testified, by invitation, before the Texas House of Representatives.
I submitted pro bono amicus curiae briefs and oral argument in before appellate courts in New Jersey and California.
I submitted comments on "Development of Life-Sustaining Treatment Guidelines" to the Virginia Joint Commission on Health Care (November 2016), reported http://jchc.virginia.gov/.
I participated on a multidisciplinary task force bringing MOLST to Delaware, and helped draft the DHSS regulations.
In addition to public service for the state and federal government, I am pleased to be engaged with healthcare policy making at the institutional and local levels in a pro bono capacity. Among other things:
I serve on the Minnesota Medical Association POLST Task Force.
I serve on the Litigation Advocacy Advisory Committee, Compassion & Choices .
I make frequent presentations to community and professional groups on health policy issues.
I have consulted with lead counsel in appellate litigation concerning medical treatment issues.
I served on a large hospital system's ethics committee (Christiana Care Health System).
I served on the institutional review board (IRB) of Widener University.
I served on the Board of the Delaware End-of-Life Coalition.
I served on a regional long-term care ethics committee in New Jersey.
I am pleased to be engaged with healthcare policy making at the institutional, local, and national levels. Among other things:
I am a member of MEDCAC, the Medicare Evidence Development & Coverage Advisory Committee (2013-2015). MEDCAC reviews and evaluates medical literature, technology assessments, and examines data and information on the effectiveness and appropriateness of medical items and services that are covered under Medicare, or that may be eligible for coverage under Medicare. MEDCAC judges the strength of the available evidence and makes recommendations to CMS based on that evidence.
I co-chair the Minnesota POLST Task Force, a project housed by the Minnesota Medical Association
I testified, by invitation, before the U.S. President's Council on Bioethics.
I testified, by invitation, before the Minnesota Senate.
I testified, by invitation, before the Texas House of Representatives.
I submitted pro bono amicus curiae briefs and oral argument in before appellate courts in New Jersey and California.
I participated on a multidisciplinary task force bringing MOLST to Delaware, and helped draft the DHSS regulations.
MEDCAC, Medicare Evidence Development & Coverage Advisory Committe
Appointed by the U.S. Department of Health & Human Services to Advise the Centers for Medicare & Medicaid Services (CMS), 2013 –
Minnesota Medical Association, Minneapolis, MN
POLST Task Force, February 2012 –
POLST Model Legislation Task Force
Drafted best practices guidance for state legislatures, 2013 – 2014
Delaware MOLST Task Force, Wilmington, DE
Legal Representative, March 2009 – December 2011
Regulations Drafting Subcommittee, May 2010 – August 2011
Human Services Committee, Texas House of Representatives
Invited testimony: Patient and Family Treatment Choice Rights Act of 2011, H.B. 3520 (April 12, 2011).
New Jersey Appellate Division
Pro Bono Amicus Brief: Betancourt v. TrinitasHospital, No. A-003849-08T2 (N.J. Super. A.D. filed Sept. 10, 2009).
President’s Council on Bioethics
Invited testimony: Medical Futility: Institutional and Legislative Initiatives (September 12, 2008).